Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196695 | 1.00 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL197117 | 1.00 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Ammonia Solution, Strong SCHEMBL28728215 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL21059082 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Chloromethane SCHEMBL29259265 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL28431532 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL18770586 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL4576488 | 0.89 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL27695113 | 0.89 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Leucine SCHEMBL9119565 | 0.87 | SLC7A5 (0.72) | SLC7A5GRIK1SLC1A2SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| WO-2013004716-A1 | PEPTIDE BEADS | UNIVERSITÄT BASEL (CH) | 2013-01-10 | — | — | WO | claimed |
| EP-2068878-A2 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | claimed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | claimed |
| WO-2008036540-A2 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | claimed |
| US-6858585-B1 | Cyclic depsipeptides and drugs containing the same as the active ingredient | NISSHIN SEIFUN GROUP INC. (JP) | 2005-02-22 | — | — | US | claimed |
| EP-0967222-A1 | CYCLIC DEPSIPEPTIDES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Nisshin Flour Milling Co., Ltd. (JP) | 1999-12-29 | — | — | EP | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | claimed |
| JP-7274985-A | — | — | None | — | — | JP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
| CN-1099392-A | Compounds containing a fused bicyclic ring and processes therefor | BRISTOL MYERS SQIBB COMPANY (US) | 1995-03-01 | — | — | CN | disclosed |
| EP-0629627-A2 | Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | SLC7A5 374/4885PTGS1 3842/4885SLC7A11 1221/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | SLC7A5 3300/4885PTGS1 3992/4885SLC7A11 1828/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | SLC7A5 4027/4885PTGS1 15/4885SLC7A11 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.